Fetal bovine serum (FBS) is commonly used in cell culture growth media and is derived from blood drawn from fetal calves which is a by-product of the beef industry. It is heat-inactivated to neutralize any complement proteins present from the serum. FBS contains growth-promoting proteins like insulin, transferrin and other components which support the growth of mammalian cells in cultures. It is an essential reagent for in vitro cell culture and is used extensively in research, bioproduction and manufacturing applications.

The fetal bovine serum market is estimated to be valued at USD 1.86 Bn in 2024 and is expected to reach USD 4.54 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 13.6% from 2024 to 2031.

The increasing R&D investments in pharmaceutical and biotechnology industries is primarily driving the Fetal Bovine Serum Market Demand. FBS finds widespread application in research related to drug discovery, life sciences and development of new diagnostics and vaccines.

Key Takeaways

Key players operating in the fetal bovine serum market are Merck KGaA, Thermo Fisher Scientific Inc., HiMedia Laboratories, Bio-Techne, PAN-Biotech, Atlas Biologicals, Inc., Rocky Mountain Biologicals, Cytiva, Sartorius AG, and SeraCare Life Sciences. These players are focusing on innovation, partnerships and robust supply chains to cater to the growing demand.

Get More Insights on- Fetal Bovine Serum Market